Wikipedia

Ihe na-eme ka ihe na-egbuke egbuke

Lucinatant nke aha azumahia bu Surfacing bu medication di mmiri mmiri nke eji agwo umuaka nwere nsogbu n'iku ụme.[1] Ọ bụ ihe na-eme ka mmadụ na-arụ ọrụ n'akpa ume maka ụmụ ọhụrụ na-enweghị ihe na-emepụta ihe zuru oke n'akpa nwa ha. Ọ bụ ezie na ọgwụ ndị mbụ nke klas ahụ, dị ka beractant (Survanta & Beraksurf), Calfactant (Infasurf) , na poractant (Curosurf), sitere na ụmụ anụmanụ, lucinactant bụ ihe aka mere. U.S. Food and Drug Administration (FDA) kwadoro ya maka iji ya na United States na Machị 6, 2012. [2]

Ojiji ọgwụ

dezie

A na-egosi Lucinactant iji melite ọrụ akpa ume ma belata oge na ihe ize ndụ nke ikuku ikuku n'ime ụmụaka. Enwere ike iji ya ruo afọ abụọ ma kọwaa ya maka ụmụaka a chọpụtara na ha nwere nsogbu iku ume siri ike na-esote nje dịka RSV ma ọ bụ influenza, gụnyere H1N1. [3] [4][5] A na-ejikwa Lucinactant agwọ ọrịa meconium aspiration syndrome.[3][6]

Akụkọ ihe mere eme

dezie

E debere ntọala sayensị maka lucinactant na ụlọ nyocha nke Charles Cochrane na Scripps Research Institute na 1990s.[7] Ọ bụ Discovery Laboratories nke Warrington, PA mepụtara ọgwụ ahụ. Ụzọ site na usoro nkwenye ahụ dị ogologo n'ụzọ a na-adịghị ahụkebe, na-egosipụta n'akụkụ ụfọdụ ihe ịma aka na usoro mmepụta nke dị mkpa ka a dozie tupu e nye nkwenye.[8]

  1. ↑ Surfaxin. Discovery Labs. Archived from the original on April 20, 2009.
  2. ↑ FDA approves Surfaxin to prevent breathing disorder in premature infants. Fda.gov (2012-03-06). Retrieved on 2012-10-20.
  3. ↑ "POPG, a Key Component of Discovery Labs' KL4 Surfactant, Identified as a Novel Anti-Viral Therapeutic Approach".
  4. ↑ (October 1999) "Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome". American Journal of Respiratory and Critical Care Medicine 160 (4): 1188–95. DOI:10.1164/ajrccm.160.4.9808118. PMID 10508806. 
  5. ↑ (March 2005) "Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome". Expert Opinion on Investigational Drugs 14 (3): 329–34. DOI:10.1517/13543784.14.3.329. PMID 15833063. 
  6. ↑ (June 2002) "A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome". Pediatrics 109 (6): 1081–7. DOI:10.1542/peds.109.6.1081. PMID 12042546. 
  7. ↑ Scripps Research Discoveries Lead to Newly Approved Drug for Infant Respiratory Distress Syndrome. Scripps.edu (2012-03-06). Retrieved on 2012-10-20.
  8. ↑ Pharmaceutical News - Discovery Labs Turns Focus To Surfaxin Market Strategy - October 20, 2012. Pharmacy Choice. Retrieved on 2012-10-20.
Ewepụtara na https://ig.wikipedia.org/w/index.php?title=Ihe_na-eme_ka_ihe_na-egbuke_egbuke&oldid=166852